Modulating MGMT expression through interfering with cell signaling pathways

Guanine O-6-alkylating agents are widely used as first-line chemotherapeutic drugs due to their ability to induce cytotoxic DNA damage. However, a major hurdle in their effectiveness is the emergence of chemoresistance, largely attributed to the DNA repair pathway mediated by O-6-methylguanine-DNA methyltransferase (MGMT). MGMT plays an important role in removing the alkyl groups from lethal O-6-alkylguanine (O-6-AlkylG) adducts formed by chemotherapeutic alkylating agents. By doing so, MGMT enables tumor cells to evade apoptosis and develop drug resistance toward DNA alkylating agents. Although covalent inhibitors of MGMT, such as O(6)benzylguanine (O-6-BG) and O-6-(4-bromothenyl)guanine (O-6-4-BTG or lomeguatrib), have been explored in clinical settings, their utility is limited due to severe delayed hematological toxicity observed in most patients when combined with alkylating agents. Therefore, there is an urgent need to identify new targets and unravel the underlying molecular mechanisms and to develop alternative therapeutic strategies that can overcome MGMTmediated tumor resistance. In this context, the regulation of MGMT expression via interfering the specific cell signaling pathways (e.g., Wnt/beta-catenin, NF-kappa B, Hedgehog, PI3K/AKT/mTOR, JAK/STAT) emerges as a promising strategy for overcoming tumor resistance, and ultimately enhancing the efficacy of DNA alkylating agents in chemotherapy.

Automated summary

Guanine O-6-alkylating agents, as first-line chemotherapeutic drugs, induce cytotoxic DNA damage but face the challenge of chemoresistance caused by O-6-methylguanine-DNA methyltransferase (MGMT) repair pathway. Covalent inhibitors of MGMT have limited utility due to severe delayed hematological toxicity. Therefore, targeting specific cell signaling pathways that regulate MGMT expression emerges as a promising strategy to overcome tumor resistance and enhance the efficacy of DNA alkylating agents in chemotherapy.